JTC2016 (closed)
Heart failure
Facts and figures
Funded projects
Title
|
Coordinator
|
Partner (Countries)
|
Summary (short)
|
ACM-HF
|
Giulio Pompilio, Centro Cardiologico Monzino-IRCCS, Milan, Italy |
Germany, France, Spain, Netherlands, Slovenia |
Heart failure and life-threatening arrhythmias can be indicative of Arrhythmogenic Cardiomyopathy (ACM). In order to test potential therapeutics, this project exploits an innovative patient-derived cell model. |
Cardio-Oncology
|
Canan Nebigil, CNRS, University of Strasbourg, Strasbourg, France |
France, Germany, Italy, Taiwan, Netherlands, Turkey |
Anticancer treatments such as chemotherapy can cause heart failure. Minimising these harmful effects is the goal of the Cardio-Oncology project. |
Cardiopro
|
Jeroen Bakkers, Hubrecht Institute, Utrecht, Netherlands |
Germany, Israel, Italy |
This project examines why zebrafish naturally regenerate cardiomyocytes while mice do not. Finding the difference might contribute to developing regenerative medicine strategies for humans with ischemic heart disease. |
CLARIFY
|
Eva van Rooij, Hubrecht Institute, Utrecht, Netherlands |
Germany, France |
After myocardial damage the immune system plays an important part in cellular regenerative responses. CLARIFY investigates the communication between cardiac myocytes, cardiac stem cells and innate immune cells during ischemic heart failure. |
DETECTIN-HF
|
Hugo A. Katus, University Hospital Heidelberg, Heidelberg, Germany |
Estonia, France, Poland, Netherlands |
Up to half of the cases of dilated cardiomyopathy can be explained by genetic predisposition. Exploring the precise mechanisms leading to these variations is what this project aims at. |
EXPERT
|
Thomas Thum, Hannover Medical School, Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover, Germany |
Netherlands, Italy, Spain, France, Romania |
EXPERT will identify pathways of age-related heart failure, and explore noncoding |
FAT4HEART
|
Borja Ibanez, Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), Madrid, Spain |
Italy, France |
The project explores the potential of a high-fat diet as a therapy for dilated cardiomyopathy. |
GENPROVIC
|
Heinz-Peter Schultheiss, Institute for Cardiac Diagnostics and Therapy (IKDT), Berlin, Germany |
Germany, Italy, Spain |
GENPROVIC seeks to establish a gene profile biomarker test in order to diagnose patients with virus-induced heart diseases. |
LIPCAR-HF
|
Florence Pinet, Inserm1167, Institut Pasteur de Lille, University of Lille, Lille, Florence, France |
Germany, Spain, Italy, Poland |
The objective of this proposal is the development of the long noncoding RNA LIPCAR as a new |
LYMIT-DIS
|
Ebba Brakenhielm, INSERM, Rouen Institute for Research and Innovation in Biomedicine, France |
The Netherlands, Poland, Belgium, Spain |
Heart Failure with preserved Ejection Fraction (HFpEF) is one of the most prevalent kinds of heart disease. LYMIT-DIS examines the mechanisms involved in the cardiac diastolic dysfunction in HFpEF. |
MacroERA
|
Stefan Engelhardt, Technische Universität München, Munich, Germany |
Netherlands, Belgium |
The MacroERA project analyses the microRNA portfolio of macrophages and their role in heart failure progression. |
MINOTAUR
|
Simon Sedej, Medical University of Graz, Graz, Austria |
Germany, Portugal, France, |
The consortium tests whether caloric restriction mimetics prevent the development of diastolic dysfunction. |
PDE4Heart
|
Rodolphe Fischmeister, INSERM and University Paris-Sud, Paris, France |
Germany, Norway, Italy |
Researchers test a new gene therapy to prevent or reverse heart failure.
|
Variation
|
Yigal Pinto, University of Amsterdam, Amsterdam, Netherlands |
France, Israel, Germany |
A mutation in Lamin A/C can lead to treatment-resistant forms of severe cardiomyopathy. VARIATION explores novel RNA based therapies targeting the mutated allele. |